drugset / Trial / NCT02728492
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Quisinostat besides its own efficacy, which can potentially lead to better results of polychemotherapy and increase the mean time to progression, it may be demonstrated that Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg combined with standard backbone chemotherapy in patients with non-small cell lung cancer (second line) and ovarian cancer (second and subsequent lines) will be investigated.
Timeline
- Start
- 2013-08
- Primary completion
- 2015-12
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quisinostat | Small molecule | 8 mg | — |
| Subject | Quisinostat | Small molecule | 10 mg | — |
| Subject | Quisinostat | Small molecule | 12 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |